JP7874664B2 - 複数のタスキニモド粒子およびその使用 - Google Patents

複数のタスキニモド粒子およびその使用

Info

Publication number
JP7874664B2
JP7874664B2 JP2023570225A JP2023570225A JP7874664B2 JP 7874664 B2 JP7874664 B2 JP 7874664B2 JP 2023570225 A JP2023570225 A JP 2023570225A JP 2023570225 A JP2023570225 A JP 2023570225A JP 7874664 B2 JP7874664 B2 JP 7874664B2
Authority
JP
Japan
Prior art keywords
particles
cancer
tascinimod
pharmaceutical
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023570225A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520307A5 (enExample
JP2024520307A (ja
Inventor
ウェンマン，ハンス
Original Assignee
アクティブ バイオテック エイビー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクティブ バイオテック エイビー filed Critical アクティブ バイオテック エイビー
Publication of JP2024520307A publication Critical patent/JP2024520307A/ja
Publication of JP2024520307A5 publication Critical patent/JP2024520307A5/ja
Application granted granted Critical
Publication of JP7874664B2 publication Critical patent/JP7874664B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Powder Metallurgy (AREA)
JP2023570225A 2021-05-25 2022-05-23 複数のタスキニモド粒子およびその使用 Active JP7874664B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21175623.4 2021-05-25
EP21175623 2021-05-25
PCT/EP2022/063887 WO2022248401A1 (en) 2021-05-25 2022-05-23 A plurality of tasquinimod particles and use thereof

Publications (3)

Publication Number Publication Date
JP2024520307A JP2024520307A (ja) 2024-05-24
JP2024520307A5 JP2024520307A5 (enExample) 2025-05-21
JP7874664B2 true JP7874664B2 (ja) 2026-06-16

Family

ID=76098832

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023570225A Active JP7874664B2 (ja) 2021-05-25 2022-05-23 複数のタスキニモド粒子およびその使用

Country Status (14)

Country Link
US (2) US12485095B2 (enExample)
EP (1) EP4346773B1 (enExample)
JP (1) JP7874664B2 (enExample)
KR (1) KR20240012436A (enExample)
CN (1) CN117295492A (enExample)
AU (1) AU2022281056A1 (enExample)
BR (1) BR112023023715A2 (enExample)
CA (1) CA3218977A1 (enExample)
ES (1) ES3048983T3 (enExample)
IL (1) IL308542A (enExample)
MX (1) MX2023013301A (enExample)
PL (1) PL4346773T3 (enExample)
WO (1) WO2022248401A1 (enExample)
ZA (1) ZA202311594B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025228998A1 (en) * 2024-04-30 2025-11-06 Institut National de la Santé et de la Recherche Médicale Use of hdac4 inhibitors for the treatment of melanoma

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512454A (ja) 1999-10-25 2003-04-02 アクティブ バイオテック エイビー 悪性腫瘍治療薬
JP2016514707A (ja) 2013-03-15 2016-05-23 アイシューティカ インク．Ｉｃｅｕｔｉｃａ Ｉｎｃ． アビラテロン酢酸エステル製剤
JP2017534652A (ja) 2014-11-19 2017-11-24 アクティブ バイオテック エイビー 白血病の治療に使用するためのキノリンカルボキサミド
WO2018208993A1 (en) 2017-05-09 2018-11-15 Dignity Health Drug delivery composition and method of fabrication
JP2020114888A (ja) 2010-03-19 2020-07-30 ボストン バイオメディカル， インコーポレイテッド がん幹細胞を標的とするための新規の方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
WO2012004338A1 (en) 2010-07-09 2012-01-12 Active Biotech Ab Method for manufacturing of quinoline-3-carboxamides
EP2537517A1 (en) 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
WO2015160696A1 (en) 2014-04-14 2015-10-22 Yale University Compositions and methods of inhibiting histone deacetylases
EP3041472B1 (en) 2014-09-23 2017-02-01 Active Biotech AB Quinoline carboxamides for use in the treatment of multiple myeloma
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
WO2018105943A1 (ko) 2016-12-07 2018-06-14 순천향대학교 산학협력단 폐섬유증 또는 천식의 치료 또는 완화용 약학 조성물
US20230293512A1 (en) 2020-07-23 2023-09-21 Erasmus University Medical Center Rotterdam S100 proteins as novel therapeutic targets in myeloproliferative neoplasms
WO2022152902A1 (en) 2021-01-18 2022-07-21 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512454A (ja) 1999-10-25 2003-04-02 アクティブ バイオテック エイビー 悪性腫瘍治療薬
JP2020114888A (ja) 2010-03-19 2020-07-30 ボストン バイオメディカル， インコーポレイテッド がん幹細胞を標的とするための新規の方法
JP2016514707A (ja) 2013-03-15 2016-05-23 アイシューティカ インク．Ｉｃｅｕｔｉｃａ Ｉｎｃ． アビラテロン酢酸エステル製剤
JP2017534652A (ja) 2014-11-19 2017-11-24 アクティブ バイオテック エイビー 白血病の治療に使用するためのキノリンカルボキサミド
WO2018208993A1 (en) 2017-05-09 2018-11-15 Dignity Health Drug delivery composition and method of fabrication

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Jalay T. Joshi，A Review on Micronization Techniques，J. of Pharmaceuticals Sciences and technology，2011年，3 (7)，651-681
Panoma Chakravarty et al.，Using Supercritical Fluid Technology as a Green Alternative During the Preparation of Drug Delivery Systems，Pharmaceuticus，2019年，11，arn629
Tushar Gohil，Solubility enhancement of poorly water soluble drugs，Indonesian J. Pharm.，2014年，25 (1)，1-8

Also Published As

Publication number Publication date
EP4346773B1 (en) 2025-07-02
US20260076908A1 (en) 2026-03-19
ZA202311594B (en) 2025-04-30
ES3048983T3 (en) 2025-12-12
US20240285532A1 (en) 2024-08-29
KR20240012436A (ko) 2024-01-29
JP2024520307A (ja) 2024-05-24
BR112023023715A2 (pt) 2024-02-20
PL4346773T3 (pl) 2025-11-03
MX2023013301A (es) 2023-12-04
AU2022281056A1 (en) 2023-11-30
IL308542A (en) 2024-01-01
EP4346773C0 (en) 2025-07-02
US12485095B2 (en) 2025-12-02
EP4346773A1 (en) 2024-04-10
CN117295492A (zh) 2023-12-26
WO2022248401A1 (en) 2022-12-01
CA3218977A1 (en) 2022-12-01

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250512

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260417

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260519

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260604

R150 Certificate of patent or registration of utility model

Ref document number: 7874664

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150